Spiriva HandiHaler approved for the reduction of COPD exacerbations

SPIRIVA (tiotropium) powder for oral inhalation by Boehringer Ingelheim and Pfizer
SPIRIVA (tiotropium) powder for oral inhalation by Boehringer Ingelheim and Pfizer
Spiriva HandiHaler (tiotropium powder for oral inhalation, from Boehringer Ingelheim and Pfizer) has been approved by the FDA for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). This approval was based on data from two clinical trials in nearly 8,000 COPD patients: the UPLIFT (Understanding the Potential Long-term Impacts on Function with Tiotropium) study and a six-month study conducted in the Veterans Affairs setting. While the UPLIFT trial did not meet its primary endpoint (slowing the rate of decline in lung function versus placebo), it provided relevant and important clinical information regarding the effect of Spiriva HandiHaler on COPD exacerbations.

The Spiriva HandiHaler prescribing information now also includes data from the UPLIFT study which demonstrated that Spiriva HandiHaler sustained improved lung function over four years when compared with placebo and reduced COPD exacerbations, even with the use of respiratory medications with the exception of inhaled anticholinergics.

Spiriva HandiHaler is already indicated for the long-term maintenance treatment of bronchospasm due to chronic bronchitis and emphysema.

For more information call (800) 542-6257 or visit www.spiriva.com.